Novartis looks for silver lining in $2B canakinumab repurposing after 2nd lung cancer failurenews2021-10-25T13:57:47+00:00October 25th, 2021|Fierce Pharma|
J&J’s COVID-19 vaccine maker in South Africa opens line for anesthetics: reportnews2021-10-25T13:30:29+00:00October 25th, 2021|Fierce Pharma|
Bristol Myers Squibb, after passing on Acceleron, now eyes Aurinia takeout: Bloombergnews2021-10-22T20:15:00+00:00October 22nd, 2021|Fierce Pharma|
Oncopeptides’ shares crash as it pulls Pepaxto from the market, plans to shut down commercial unitsnews2021-10-22T19:27:20+00:00October 22nd, 2021|Fierce Pharma|
Pfizer’s COVID-19 vaccine is safe, effective in kids ages 5 to 11, setting up possible FDA nodnews2021-10-22T15:18:29+00:00October 22nd, 2021|Fierce Pharma|
Buckle up AbbVie, Amgen: Biohaven’s oral CGRP drug is gaining traction in migraine, doctors’ survey showsnews2021-10-22T14:37:29+00:00October 22nd, 2021|Fierce Pharma|
Lilly breached a contract by not paying royalties on big-selling diabetes meds, court findsnews2021-10-22T14:35:58+00:00October 22nd, 2021|Fierce Pharma|
Sanofi and Regeneron’s Dupixent aces another test, this time in the debilitating itch condition prurigo nodularisnews2021-10-22T14:16:31+00:00October 22nd, 2021|Fierce Pharma|
FDA greenlights Genentech’s eye implant for macular degeneration. Will it be a tough sell?news2021-10-22T11:51:12+00:00October 22nd, 2021|Fierce Pharma|
Fierce Pharma Asia—Hansoh’s siRNA deals; J&J preps for Legend’s CAR-T launch; Brii’s COVID antibodiesnews2021-10-22T09:59:18+00:00October 22nd, 2021|Fierce Pharma|
